Prostate CancerPhase 3CheckMate 7DXNCT04100018
A Study of Nivolumab or Placebo in Combination With Docetaxel in Men With Advanced Castration-resistant Prostate Cancer
A Phase 3 study testing Nivolumab, Prednisone and Docetaxel in people with Prostate Cancer, run by Bristol-Myers Squibb at 293 sites in 28 countries.
Trial summary
The purpose of this study is to assess the safety and effectiveness of nivolumab with docetaxel in men with advanced castration resistant prostate cancer who have progressed after second-generation hormonal manipulation. Read more about this study
- Who is it for?
- Ages 18 years and older, men only
- Conditions the study is for
- Prostate Cancer
- What is being tested?
- Nivolumab, Prednisone and Docetaxel
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 1,030 participants
- Where
- 293 sitesin 28 countries
- Study dates
- 6 Feb 2020to 25 Jun 2024
- Phase
- Phase 3
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- Men only
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Histologic confirmation of adenocarcinoma of the prostate without small cell features
- Current evidence of metastatic disease documented by either bone lesions on radionuclide bone scan and/or soft tissue lesions on computerized tomography/magnetic resonance imaging (CT/MRI)
- Eastern Cooperative Oncology Group (ECOG) performance status 0-1
- Ongoing androgen deprivation therapy (ADT) with a gonadotropin-releasing hormone (GnRH) analogue or bilateral orchiectomy
- Documented prostate cancer progression per Prostate Cancer Working Group (PCWG3) criteria within 6 months prior to screening
- Chemotherapy-naïve for metastatic castration-resistant prostate cancer (mCRPC), with 1 to 2 prior second generation hormonal therapies in the recurrent non-metastatic setting and/or metastatic setting, and no more than 1 second generation hormonal therapy in the mCRPC setting. Must have progressed during or after second generation hormonal therapy or have documented intolerance to second generation hormonal therapy
- Participants must meet one of the following criteria regarding tissue submission: Sufficient tumor samples from a newly obtained ("fresh") biopsy (obtained during screening); or archival tumor tissue in the form of formalin-fixed paraffin-embedded (FFPE) block or unstained tumor tissue slides. For participants with bone-only disease or inaccessible soft tissue lesions or if the biopsy procedure would pose an unacceptable clinical risk for the participant, submission of tumor tissue obtained from a fresh biopsy is not required.
- Men must agree to follow specific methods of contraception, if applicable
Who cannot join
- Active brain metastases
- Active, known, or suspected autoimmune disease
- Condition requiring systemic treatment with corticosteroids (> 10 mg daily prednisone equivalent) or other immunosuppressive medications within 14 days of start of study treatment. Inhaled or topical steroids or adrenal replacement steroid doses are permitted in the absence of active autoimmune disease
- Prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CTLA-4 antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways
- Prior treatment with docetaxel or other chemotherapy for mCRPC. Prior docetaxel for metastatic castration-sensitive prostate cancer is permitted if at least 12 months have elapsed from last dose of docetaxel
- Other protocol-defined inclusion/exclusion criteria apply
Trial locations and contacts
293 sites in 28 countries.
293 sites in 28 countries
United States45 sites
Local Institution - 0300
Albany, New York, 12208
Local Institution - 0180
Allentown, Pennsylvania, 18103-6218
Local Institution - 0012
Anchorage, Alaska, 99503
Local Institution - 0117
Atlanta, Georgia, 30342
Local Institution - 0286
Austin, Texas, 75251
Local Institution - 0074
Bala-Cynwyd, Pennsylvania, 19004
Local Institution - 0150
Baltimore, Maryland, 21201
Local Institution - 0332
Brandywine, Maryland, 20613
Local Institution - 0233
Charleston, South Carolina, 29414
Local Institution - 0333
Columbus, Ohio, 43210
Local Institution - 0303
Dallas, Texas, 75251
Local Institution - 0087
Denver, Colorado, 80211-5222
Local Institution - 0365
East Brunswick, New Jersey, 08816
Local Institution - 0139
Florham Park, New Jersey, 07932
Local Institution - 0183
Fort Wayne, Indiana, 46804
Local Institution - 0149
Germantown, Tennessee, 38138
Local Institution - 0196
Hollywood, Florida, 33021
Local Institution - 0284
Houston, Texas, 77024-2843
Local Institution - 0195
Houston, Texas, 77030-3721
Local Institution - 0397
Jacksonville, Florida, 32256
Local Institution - 0269
Jonesboro, Arkansas, 72401
Local Institution - 0164
Lakeland, Florida, 33805
Local Institution - 0302
Louisville, Kentucky, 40202
Local Institution - 0126
Marietta, Georgia, 30060
Local Institution - 0305
Mobile, Alabama, 36608-1753
Local Institution - 0115
Myrtle Beach, South Carolina, 29572-4607
Local Institution - 0287
Niles, Illinois, 60714
Local Institution - 0299
Omaha, Nebraska, 68130
Local Institution - 0179
Orange, California, 92868
Local Institution - 0181
Orlando, Florida, 32806
Local Institution - 0285
Pensacola, Florida, 32503
Local Institution - 0292
Pittsburgh, Pennsylvania, 15232
Local Institution - 0028
Port Jefferson Station, New York, 11776
Local Institution - 0055
Rancho Mirage, California, 92270
Local Institution - 0260
Redondo Beach, California, 90277
Local Institution - 0011
San Antonio, Texas, 78229
Local Institution - 0081
Santa Monica, California, 90404
Local Institution - 0110
Seattle, Washington, 98109
Local Institution - 0289
Spokane, Washington, 99208
Local Institution - 0382
Thomasville, Georgia, 31792
Local Institution - 0293
Tucson, Arizona, 85724
The University of Texas Health Science Center at Tyler DBA UT Health East Texas Hope Cancer Center
Tyler, Texas, 75701
Local Institution - 0366
Washington D.C., District of Columbia, 20010-3017
Local Institution - 0190
West Haven, Connecticut, 06516-5907
Local Institution - 0177
Weston, Florida, 33331
China27 sites
Local Institution - 0320
Baoding Shi, Hebei, 071000
Local Institution - 0245
Beijing, Beijing Municipality, 100020
Local Institution - 0140
Beijing, Beijing Municipality, 100034
Local Institution - 0254
Beijing, Beijing Municipality, 100036
Local Institution - 0337
Beijing, Beijing Municipality, 100050
Local Institution - 0345
Beijing, Beijing Municipality, 100730
Local Institution - 0312
Beijing, Bei, 100071
Local Institution - 0168
Changsha, Hunan, 410031
Local Institution - 0253
Chengdu, Sichuan, 610041
Local Institution - 0256
Fuzhou, Fujian, 350001
Local Institution - 0319
Guangzhou, Guangdong, 510000
Local Institution - 0316
Hangzhou, Zhejiang, 310003
Local Institution - 0344
Hangzhou, Zhejiang, 310014
Local Institution - 0224
Harbin, Heilongjiang, 150081
Local Institution - 0314
Henan Sheng, Henan, 450003
Local Institution - 0326
Jinan, Shandong, 250012
Local Institution - 0347
Nanchang, Jiangxi, 330006
Local Institution - 0330
Nanchang, Jiangxi, 330029
Local Institution - 0165
Nanjing, Jiangsu, 210000
Local Institution - 0317
Nanjing, Jiangsu, 210009
Local Institution - 0325
Nanjing, Jiangsu, 210009
Local Institution - 0155
Shanghai, Shanghai Municipality, 200032
Local Institution - 0161
Shenyang, Liaoning, 110042
Local Institution - 0310
Ürümqi, Xinjiang, 830011
Local Institution - 0313
Wuhan, Hubei, 430000
Local Institution - 0353
Xi'an, Shannxi, 710061
Local Institution - 0275
Zhengzhou, Henan, 450003
Japan24 sites
Local Institution - 0340
Akita, Akita, 010-8543
Local Institution - 0346
Chiba, Chiba, 260-8717
Local Institution - 0280
Fukuoka, Fukuoka, 8128582
Local Institution - 0309
Hamamatsu, Shizuoka, 431-3192
Local Institution - 0358
Hirosaki-shi, Aomori, 036-8563
Local Institution - 0342
Kamigyō-ku, Kyoto, 602-8566
Local Institution - 0355
Kashihara-shi, Nara, 6348522
Local Institution - 0324
Kumamoto, Kumamoto, 860-0008
Local Institution - 0307
Matsuyama, Ehime, 791-0280
Local Institution - 0341
Nagasaki, 8528501
Local Institution - 0362
Nagoya, Aichi-ken, 4678602
Local Institution - 0327
Niigata, 951-8520
Local Institution - 0354
Okayama, 7000914
Local Institution - 0343
Osaka, Osaka, 5418567
Local Institution - 0338
Osaka, 565-0871
Local Institution - 0323
Ōsaka-sayama, Osaka, 5898511
Local Institution - 0339
Sakura-Shi, Chiba, 285-8741
Local Institution - 0281
Sapporo, Hokkaido, 0608543
Local Institution - 0296
Sapporo, Hokkaido, 608648
Local Institution - 0308
Tokyo, 1608582
Local Institution - 0279
Toyama, Toyama, 9300194
Local Institution - 0282
Ube Shi, Yamaguchi, 7550046
Local Institution - 0278
Wakayama, 641-8510
Local Institution - 0283
Yokohama, Kanagawa, 2320024
France19 sites
Local Institution - 0107
Angers, 49055
Local Institution - 0202
Brest, 29200
Local Institution - 0398
Dijon, 21079
Local Institution - 0030
Hyères, 83400
Local Institution - 0167
Le Mans, Sarthe, 72000
Local Institution - 0079
Lille, Nord, 59020
Local Institution - 0395
Montpellier, 34070
Local Institution - 0109
Montpellier, 34295
Local Institution - 0384
Nice, 06189
Local Institution - 0068
Nîmes, 30029
Local Institution - 0381
Paris, 75013
Local Institution - 0106
Paris, 75014
Local Institution - 0071
Paris, 75015
Local Institution - 0133
Pierre-Bénite, 69310
Local Institution - 0399
Reims, 51100
Local Institution - 0380
Rennes, 35042 Rennes
Local Institution - 0105
Strasbourg, Alsace, 67200
Local Institution - 0387
Strasbourg, 67000
Local Institution - 0271
Villejuif, 94805
Brazil17 sites
Local Institution - 0097
Belo Horizonte, Minas Gerais, 30110022
Local Institution - 0022
Belo Horizonte, Minas Gerais, 30130090
Local Institution - 0086
Campinas, São Paulo, 13083 970
Local Institution - 0100
Curitiba, Paraná, 80530-010
Local Institution - 0082
Curitiba, Paraná, 80810050
Local Institution - 0058
Ijuí, Rio Grande do Sul, 98700-000
Local Institution - 0321
Natal, Rio Grande do Norte, 59075-740
Local Institution - 0063
Porto Alegre, Rio Grande do Sul, 90035-001
Local Institution - 0056
Porto Alegre, Rio Grande do Sul, 90035-903
Local Institution - 0057
Porto Alegre, Rio Grande do Sul, 90110-270
Local Institution - 0189
Rio de Janeiro, 22250-905
Local Institution - 0060
Rio de Janeiro, 22793-080
Local Institution - 0059
Santo André, São Paulo, 09060-650
Local Institution - 0096
São José do Rio Preto, São Paulo, 15090-000
Local Institution - 0080
São Paulo, 01321-001
Local Institution - 0273
São Paulo, 01327-0001
Local Institution - 0328
São Paulo, 05652- 900
Germany16 sites
Local Institution - 0089
Bonn, 53127
Local Institution - 0090
Dresden, Saxony, 01307
Local Institution - 0376
Düsseldorf, 40225
Local Institution - 0172
Emmendingen, 79312
Local Institution - 0142
Erlangen, 91054
Local Institution - 0018
Frankfurt am Main, 60590
Local Institution - 0064
Hamburg, 20246
Local Institution - 0069
Hamburg, 22763
Local Institution - 0389
Heidelberg, 69120
Local Institution - 0014
Koblenz, Rheinland Pfa, 56068
Local Institution - 0004
Magdeburg, 39120
Local Institution - 0372
Marburg, 35043
Local Institution - 0204
München, 81675
Local Institution - 0036
Münster, 48149
Local Institution - 0023
Nürtingen, Baden-Wurttemberg, 72622
Local Institution - 0169
Tübingen, 72076
Italy13 sites
Local Institution - 0099
Benevento, 82100
Local Institution - 0001
Bergamo, 24127
Local Institution - 0111
Bologna, 40138
Local Institution - 0039
Brescia, 25123
Local Institution - 0053
Cremona, 26100
Local Institution - 0066
Milan, 20141
Local Institution - 0120
Naples, 80131
Local Institution - 0070
Orbassano, 10043
Local Institution - 0037
Parma, 43126
Local Institution - 0199
Pisa, 56126
Local Institution - 0046
Rome, 00128
Local Institution - 0385
Rome, 00152
Local Institution - 0067
Trento, 38122
Spain13 sites
Local Institution - 0073
Barcelona, 08916
Local Institution - 0123
Barcelona, 8908
Local Institution - 0360
Córdoba, 14004
Local Institution - 0044
Girona, 17007
Local Institution - 0034
Lugo, 27003
Local Institution - 0076
Madrid, 28006
Local Institution - 0024
Madrid, 28033
Local Institution - 0003
Madrid, 28034
Local Institution - 0031
Madrid, 28041
Local Institution - 0364
Madrid, 28222
Local Institution - 0141
Manresa, Barcelona, 8243
Local Institution - 0124
Sabadell (Barcelona), 08208
Local Institution - 0363
Seville, 41013
South Korea12 sites
Local Institution - 0391
Daegu, 42601
Local Institution - 0298
Incheon, 405-760
Local Institution - 0375
Jeollanam-do, 58128
Local Institution - 0297
Jung-gu, Daejeon, 35015
Local Institution - 0374
Seodaemun-Gu, 3722
Local Institution - 0370
Seoul, 02841
Local Institution - 0171
Seoul, 03080
Local Institution - 0193
Seoul, 05505
Local Institution - 0187
Seoul, 06351
Local Institution - 0373
Seoul, 6591
Local Institution - 0186
Songnam-si, Gyeonggi-do, 13620
Local Institution - 0158
Yangsan, 50612
Argentina10 sites
Local Institution - 0077
Buenos Aires, 1280
Local Institution - 0178
Buenos Aires, 1426
Local Institution - 0185
Buenos Aires, C1012
Local Institution - 0369
La Rioja, F5300COE
Local Institution - 0129
Mar del Plata, Buenos Aires, B7602CBM
Local Institution - 0153
Parana, Córdoba Province, 5000
Local Institution - 0061
Pergamino, Buenos Aires, B2700
Local Institution - 0393
Río Cuarto, Córdoba Province, 5800
Local Institution - 0394
San Juan, J5402DIL
Local Institution - 0083
Viedma, Río Negro Province, 8500
Australia10 sites
Local Institution - 0379
Ballarat, Victoria, 3350
Local Institution - 0040
Frankston, Victoria, 3199
Local Institution - 0152
Gosford, New South Wales, 2250
Local Institution - 0091
Lismore, New South Wales, 2480
Local Institution - 0032
Malvern, Victoria, 3144
Local Institution - 0010
North Adelaide, South Australia, 5006
Local Institution - 0006
South Brisbane, Queensland, 4101
Local Institution - 0132
Wahroonga, New South Wales, 2076
Local Institution - 0127
Westmead, New South Wales, 2145
Local Institution - 0084
Woolloongabba, Queensland, 4102
Russia10 sites
SBHI Arkhangelsk Region - Arkhangelsk Clinical Oncological Dispensary
Arkhangelsk, 163045
SAHI Republican Clinical Oncology Dispensary of MoH of RT
Kazan', 163045
Clinical Hospital MEDSI in Otradnoye
Krasnogorsk Moscow Region, 143442
Federal State Budgetary Institution N.N. Blokhin National Medical Research Center of Oncology of the
Moscow, 115478
Sechenov University
Moscow, 119435
P.A. Herzen Moscow Oncology Research Institute
Moscow, 125284
FSBI National Medical Research Radiology Center NMRRC - A. Tsyb Medical Radiological Research Centre
Obninsk, 249036
Budgetary Healthcare Institution of Omsk Region ",Clinical Oncological Dispensary",
Omsk, 644013
Andros Clinic LLC
Saint Petersburg, 197136
Russian Scientific Centre of Radiology and Surgical Technologies n.a. acad. M.A.
Saint Petersburg, 197758
Poland7 sites
Local Institution - 0383
Bydgoszcz, 85-796
Local Institution - 0136
Koszalin, 75-581
Local Institution - 0009
Lodz, 93-513
Local Institution - 0013
Lublin, 20-090
Local Institution - 0065
Poznan, 60-848
Local Institution
Warsaw, 02 797
Local Institution - 0095
Warsaw, 04-073
United Kingdom7 sites
Local Institution - 0048
Guildford, Surrey, GU2 7XX
Local Institution - 0173
London, Greater London, SW3 6JJ
Local Institution - 0154
London, NW1 2PG
Local Institution - 0098
Manchester, Lancashire, M20 4BX
Local Institution - 0008
Northwood, Middlesex, HA6 2RN
Local Institution - 0051
Nottingham, Nottinghamshire, NG5 1PB
Local Institution - 0265
Oxford, Oxfordshire, OX4 6LB
Belgium6 sites
Local Institution - 0122
Anderlecht, Brussels Capital, 1070
Local Institution - 0121
Bruges, 8000
Local Institution - 0114
Ghent, 9000
Local Institution - 0162
Ghent, 9000
Local Institution - 0137
Turnhout, 2300
Local Institution - 0029
Wilrijk, 2610
Czechia6 sites
Local Institution - 0108
Brno, 656 53
Local Institution - 0093
Brno, 656 91
Local Institution - 0049
Olomouc, 779 00
Local Institution - 0088
Ostrava, 70852
Local Institution - 0050
Prague, 140 59
Local Institution - 0361
Prague, 180 81
Israel6 sites
Local Institution - 0072
Haifa, 3109601
Local Institution - 0388
Jerusalem, 9112001
Local Institution - 0368
Kfar Saba, 4428164
Local Institution - 0128
Petah Tikva, 4941492
Local Institution - 0135
Ramat Gan, 5265601
Local Institution - 0138
Tel Aviv, 6423906
Romania6 sites
Local Institution - 0042
Bucharest, 022328
Local Institution - 0041
Cluj-Napoca, Cluj-Napoca, 400015
Local Institution - 0043
Cluj-Napoca, 400015
Local Institution - 0020
Constanța, 900591
Local Institution - 0052
Craiova, 200347
Local Institution - 0035
Timișoara, 300425
Taiwan6 sites
Local Institution - 0192
Niaosng, Kaohsiung, 833
Local Institution - 0194
Taichung, 404
Local Institution - 0371
Taichung, 40705
Local Institution - 0386
Tainan, 704
Local Institution - 0175
Taipei, 10002
Local Institution - 0188
Taipei, 111217
Turkey (Türkiye)6 sites
Local Institution - 0094
Adana, 01330
Local Institution - 0119
Ankara, 06620
Local Institution - 0130
Ankara, 6100
Local Institution - 0113
Istanbul, 34098
Local Institution - 0104
Izmir, 35575
Local Institution - 0112
Malatya, 44280
Chile5 sites
Local Institution - 0378
Providencia, Santiago Metropolitan, 1234
Local Institution - 0026
Santiago, RM, 7630372
Local Institution - 0025
Santiago, Santiago Metropolitan, 0
Local Institution - 0377
Santiago, Santiago Metropolitan, 7500653
Local Institution - 0027
Viña del Mar, Valparaiso, 2520598
Austria4 sites
Local Institution - 0118
Linz, Upper Austria, 4020
Local Institution - 0038
Salzburg, 5020
Local Institution - 0157
Vienna, 1020
Local Institution - 0131
Vienna, 1090
Mexico4 sites
Local Institution - 0017
Mexico City, D.F., 3100
Local Institution - 0062
Morelia, Michoacán, 58260
Local Institution - 0015
Zapopan, Jalisco, 45030
Local Institution - 0016
Zapopan, Jalisco, 45070
Canada3 sites
Local Institution - 0151
Brampton, Ontario, L6R 3J7
Local Institution - 0143
Montreal, Quebec, H2X 0A9
Local Institution - 0191
Toronto, Ontario, M2K 1E1
Hong Kong3 sites
Local Institution - 0145
Hong Kong, 852
Local Institution - 0045
Hong Kong, NT
Local Institution - 0146
Hong Kong
New Zealand3 sites
Local Institution - 0101
Hamilton, 3204
Local Institution - 0184
Palmerston North, Manawatu-Wanganui, 4414
Local Institution - 0102
Tauranga, 3112
Singapore3 sites
Local Institution - 0116
Singapore, 169610
Local Institution - 0005
Singapore, 258499
Local Institution - 0170
Singapore, 308430
Puerto Rico2 sites
Local Institution - 0329
Rio Piedras, 00935
Local Institution - 0359
San Juan, 00927
About this study
Official title: A Phase 3, Randomized, Double-Blind Study of Nivolumab or Placebo in Combination With Docetaxel, in Men With Metastatic Castration-resistant Prostate Cancer
The purpose of this study is to assess the safety and effectiveness of nivolumab with docetaxel in men with advanced castration resistant prostate cancer who have progressed after second-generation hormonal manipulation.
- Conditions
- Prostate Cancer
- Being tested
- Nivolumab, Prednisone, Docetaxel, Placebo
- Medical subject headings
- Prostatic Neoplasms
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
NivolumabBiological
Also called OPDIVO,, BMS-936558-01
Specified dose on specified days
PrednisoneDrug
Specified dose on specified days
DocetaxelDrug
Specified dose on specified days
PlaceboOther
Specified dose on specified days
| Study group | Role | What they receive |
|---|---|---|
| Arm A: Nivolumab + docetaxel + prednisone | Experimental | Not described Receives: Biological: Nivolumab; Drug: Prednisone; Drug: Docetaxel |
| Arm B: Placebo + docetaxel + prednisone | Placebo comparator | Not described Receives: Drug: Prednisone; Drug: Docetaxel; Other: Placebo |
What is being measured
The primary outcome is the main question the study is designed to answer.
Radiographic Progressive Free Survival (rPFS) Assessed by Blinded Independent Central Review (BICR) Per Prostate Cancer Working Group 3 (PCWG3)
rPFS for randomized participants is the time between randomization and the first date of documented progression or death due to any cause, whichever occurs first. The rPFS was censored at the last radiographic tumor assessment up to the start of subsequent cancer therapy for those without progression or death. It was also censored at the date of last radiographic tumor assessment prior to the missed tumor assessments for participants who had progressive disease (PD) or death immediately after more than one consecutive missed tumor assessments. Radiographic progression is defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 millimeter (mm). The appearance of one or more new lesions is also considered progression.
Measured: from randomization to the first date of documented progression or death due to any cause, whichever occurs first (up to approximately 31 months)
Overall Survival (OS)
OS for all randomized participants is the time between randomization and the date of death from any cause. For participants who are alive, their survival time was censored at the last date that they were known to be alive. OS was censored for participants at the date of randomization if they had no follow-up.
Measured: From randomization to the date of death from any cause (Up to approximately 31 months)
Secondary outcomes (15)
Objective Response Rate (ORR) Assessed by Blinded Independent Central Review (BICR) Per Prostate Cancer Working Group (PCWG3)
Objective Response Rate per PCWG3 (ORR-PCWG3) is the percentage of participants who have a confirmed complete or partial best overall response (BOR) per PCWG3 among randomized participants who have measurable disease at baseline. Complete Response (CR) is defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to < 10 mm. Partial Response (PR) is defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Baseline was defined as evaluations or events that occur before the date and time of the first dose of study treatment or evaluations on the same date and time of the first dose of study treatment were also considered as baseline evaluations.
Measured: From date of randomization to the date of objectively documented progression per PCWG3 or the date of subsequent systemic cancer therapy, whichever occurs first (Up to approximately 52 months)
Time to Response (TTR) Assessed by Blinded Independent Central Review (BICR) Per Prostate Cancer Working Group (PCWG3)
Time to Response per PCWG3 (TTR-PCWG3) is the time from randomization to the date of the first documented CR or PR per PCWG3, as determined by BICR. Complete Response (CR) is defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to < 10 mm. Partial Response (PR) is defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters.
Measured: From randomization to the date of the first documented CR or PR (Up to approximately 52 months)
Duration of Response Assessed by Blinded Independent Central Review (BICR) Per Prostate Cancer Working Group (PCWG3)
Duration of Response per PCWG3 (DOR-PCWG3) is time between the date of first response (CR/PR per PCWG3) to the date of first documented radiographic progression per PCWG3,as determined by BICR, or death due to any cause whichever occurs first. Complete Response (CR) is defined as disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to < 10 mm. Partial Response (PR) is defined as at least a 30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. Radiographic progression was defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 millimeter (mm). The appearance of one or more new lesions is also considered progression.
Measured: From randomization date to the date of first documented radiographic progression or death due to any cause whichever occurs first (Up to approximately 52 months)
Prostate-specific Antigen (PSA) Response Rate (PSA-RR)
PSA Response Rate (PSA-RR) is the percentage of randomized participants with a 50% or greater decrease in PSA from baseline to the lowest post-baseline PSA result. A second consecutive value obtained 3 or more weeks later is required to confirm the PSA response. Baseline was defined as valuations or events that occur before the date and time of the first dose of study treatment or evaluations on the same date and time of the first dose of study treatment were also considered as baseline evaluations.
Measured: Up to approximately 52 months
Time to PSA Progression (TTP-PSA)
Time to PSA Progression (TTP-PSA) is the time between randomization to the date of PSA progression per PCWG3 in randomized participants. PSA Progression: For participants with an initial PSA decline from baseline, the date of PSA progression is the date that an increase of 25% or more and an absolute increase of 2 ng/mL or more from the nadir are documented and confirmed by a second consecutive PSA value at least 3 weeks later. For participants with no PSA decline from baseline, the date of PSA progression is date that an increase of 25% or more and an absolute increase of 2 ng/mL or more from baseline are documented at or beyond Week 13. Baseline was defined as valuations or events that occur before the date and time of the first dose of study treatment or evaluations on the same date and time of the first dose of study treatment were also considered as baseline evaluations. Censored at date of last PSA evaluation on/prior to start of subsequent cancer therapy.
Measured: from randomization to the date of PSA Progression (Up to approximately 31 months)
Number of Participants With Adverse Events
An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (such as an abnormal laboratory finding), symptom, or disease temporally associated with the use of study treatment, whether or not considered related to the study treatment.
Measured: From first dose and 30 days after last dose of study therapy (Up to approximately 25 months)
Number of Participants With Serious Adverse Events
Serious Adverse Event (SAE) is defined as any untoward medical occurrence that, at any dose results in death or Is life-threatening or requires inpatient hospitalization or causes prolongation of existing hospitalization or results in persistent or significant disability/incapacity or is a congenital anomaly/birth defect.
Measured: From first dose and 30 days after last dose of study therapy (Up to approximately 25 months)
Number of Participants With Adverse Events Leading to Discontinuation
An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (such as an abnormal laboratory finding), symptom, or disease temporally associated with the use of study treatment, whether or not considered related to the study treatment.
Measured: From first dose and 30 days after last dose of study therapy (Up to approximately 25 months)
Number of Participants With Endocrine Immune-Mediated Adverse Events
Immune-mediated adverse events are AEs consistent with an immune-mediated mechanism or immune-mediated component for which non-inflammatory etiologies (eg, infection or tumor progression) have been ruled out. IMAEs can include events with an alternate etiology which were exacerbated by the induction of autoimmunity. An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (such as an abnormal laboratory finding), symptom, or disease temporally associated with the use of study treatment, whether or not considered related to the study treatment.
Measured: From first dose and 100 days after last dose of study therapy (Up to approximately 13 months)
Number of Participants With Non-Endocrine Immune-Mediated Adverse Events
Immune-mediated adverse events are AEs consistent with an immune-mediated mechanism or immune-mediated component for which non-inflammatory etiologies (eg, infection or tumor progression) have been ruled out. IMAEs can include events with an alternate etiology which were exacerbated by the induction of autoimmunity. An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (such as an abnormal laboratory finding), symptom, or disease temporally associated with the use of study treatment, whether or not considered related to the study treatment.
Measured: From first dose and 100 days after last dose of study therapy (Up to approximately 13 months)
Number of Participants With Select Adverse Events
An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a preexisting medical condition in a clinical investigation participant administered study treatment and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (such as an abnormal laboratory finding), symptom, or disease temporally associated with the use of study treatment, whether or not considered related to the study treatment.
Measured: From first dose and 30 days after last dose of study therapy (Up to approximately 25 months)
Number of Participants Who Died
Measured: Up to approximately 52 months
Number of Participants With Worst Common Terminology Criteria (CTC) Grade Laboratory Test Grade Change From Baseline
The severity of laboratory test results were graded based upon the participants symptoms according to the Common Terminology Criteria for Adverse Events (CTCAE, Version 5.0); Hematology parameters were evaluated for severity according to the following scale: Grade 0 is defined as absence of an AE or within normal limits; Grade 1 = Mild - transient or mild discomfort; no medical intervention required; Grade 2 = Moderate - mild to moderate limitation in activity; Grade 3 = Severe; Grade 4 = Life threatening. Number of participants with worst grade change results to Grade 3 or Grade 4 laboratory test results is presented. E.g., the row title HEMOGLOBIN Grade 0 to Grade 3, Grade 0 is baseline and Grade 3 is post baseline.
Measured: From first dose and 30 days after last dose of study therapy (Up to approximately 25 months)
Number of Participants With Laboratory Abnormalities in Specific Thyroid Tests
Blood samples were collected for conducting specific thyroid test. Baseline is defined as evaluations or events that occur before the date and time of the first dose of study treatment. Baseline was defined as evaluations or events that occur before the date and time of the first dose of study treatment or evaluations on the same date and time of the first dose of study treatment were also considered as baseline evaluations.
Measured: From first dose and 30 days after last dose of study therapy (Up to approximately 11 months)
Time to Pain Progression as Assessed by Brief Pain Inventory-Short Form (BPI-SF)
The BPI-SF is an instrument to assess pain and includes severity and interference scores. BPI-SF is an 11-item self-report questionnaire designed to assess severity and impact of pain on daily function. Participants rate severity of pain at its "worst," "least," and "average" in last 24 hours using an 11-point numerical rating scale with anchors of "no pain" and "pain as bad. The participant's assessment of pain with BPI-SF Item number 3 (pain symptoms at their worst over the last 24 hours) form basis for analysis. Time to pain progression is time between date of randomization and date of first increase in worst pain intensity. Pain progression occurred if an increase in worst pain intensity of >= 2 points is observed from baseline and maintained over 2 consecutive time periods. Baseline was evaluations or events that occur before date and time of first dose of study treatment or evaluations on same date and time of first dose of study treatment were also considered as baseline.
Measured: From randomization to 1st pain symptoms at their worst over the last 24 hours (Up to approximately 31 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted23 Sep 2019
- Study start6 Feb 2020
- Primary completion1 Jun 2023
- Study completion25 Jun 2024
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Publications (1)Papers the sponsor has linked to this study.
- Other trials for Prostate CancerStudies of the same condition, open and under way.
- More trials run by Bristol-Myers SquibbThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 3
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind
- Who is masked
- Participant, Care provider, Investigator, Outcomes assessor
- Enrolment
- 1,030 participants (actual)
Sponsor and investigators
- Lead sponsor
- Bristol-Myers Squibb
- Sponsor type
- Industry (pharma, biotech, devices)
- Responsible party
- Sponsor
- Investigators
- Bristol-Myers Squibb, Study director, Bristol-Myers Squibb
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04100018
- Sponsor's protocol ID
- CA209-7DX
- Other IDs
- 2019-002030-36, 2019
- Acronym
- CheckMate 7DX
- Status last verified
- May 2025
- First submitted
- 20 Sep 2019
- Last updated
- 12 Jun 2025
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- Yes
- FDA-regulated drug
- Yes
- FDA-regulated device
- No
Publications
Fizazi K, Saad F, Alonso-Gordoa T, Zurawski B, Barthelemy P, Voog E, Javier Cutuli H, Buchler T, Ye D, Castellano D, Kwiatkowski M, Arslan C, Richardet M, Alifrangis C, Goh JC, Vianna K, Han W, Hatano K, Todenhofer T, Retz M, Srivastava A, Jin C, Gupta S, Trandafirescu G, Campos A, Lee CW, van Kooten Losio M, Subudhi SK. Nivolumab plus docetaxel versus placebo plus docetaxel for androgen receptor pathway inhibitor-pretreated and chemotherapy-naive metastatic castration-resistant prostate cancer (CheckMate 7DX): a double-blind, randomised, phase 3 trial. Lancet Oncol. 2026 Jan;27(1):68-78. doi: 10.1016/S1470-2045(25)00566-2.
PubMed 41449150
Study at a glance
From the registry record, last updated by the sponsor on 12 Jun 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- A Phase 3, Randomized, Double-Blind Study of Nivolumab or Placebo in Combination With Docetaxel, in Men With Metastatic Castration-resistant Prostate Cancer
- ClinicalTrials.gov ID
- NCT04100018
- Acronym / sponsor ID
- CheckMate 7DX / CA209-7DX
- Conditions
- Prostate Cancer
- Phase
- Phase 3
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 1,030 participants (actual)
- Lead sponsor
- Bristol-Myers SquibbIndustry (pharma, biotech, devices)
- Study start
- 6 Feb 2020 (actual)
- Primary completion
- 1 Jun 2023 (actual)
- Study completion
- 25 Jun 2024 (actual)
- First posted
- 23 Sep 2019 (actual)
- Results
- Posted 22 Jul 2024
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The purpose of this study is to assess the safety and effectiveness of nivolumab with docetaxel in men with advanced castration resistant prostate cancer who have progressed after second-generation hormonal manipulation.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Quadruple blind (participant, care provider, investigator, outcomes assessor)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Arm A: Nivolumab + docetaxel + prednisone | Experimental | Biological: Nivolumab, Drug: Prednisone, Drug: Docetaxel |
| Arm B: Placebo + docetaxel + prednisone | Placebo comparator | Drug: Prednisone, Drug: Docetaxel, Other: Placebo |
Who may qualify
- Ages
- 18 years and older
- Sex
- Male only
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (8 listed)
- Histologic confirmation of adenocarcinoma of the prostate without small cell features
- Current evidence of metastatic disease documented by either bone lesions on radionuclide bone scan and/or soft tissue lesions on computerized tomography/magnetic resonance imaging (CT/MRI)
- Eastern Cooperative Oncology Group (ECOG) performance status 0-1
- Ongoing androgen deprivation therapy (ADT) with a gonadotropin-releasing hormone (GnRH) analogue or bilateral orchiectomy
- Documented prostate cancer progression per Prostate Cancer Working Group (PCWG3) criteria within 6 months prior to screening
Key exclusion criteria (6 listed)
- Active brain metastases
- Active, known, or suspected autoimmune disease
- Condition requiring systemic treatment with corticosteroids (> 10 mg daily prednisone equivalent) or other immunosuppressive medications within 14 days of start of study treatment. Inhaled or topical steroids or adrenal replacement steroid doses are permitted in the absence of active autoimmune disease
- Prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CTLA-4 antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways
- Prior treatment with docetaxel or other chemotherapy for mCRPC. Prior docetaxel for metastatic castration-sensitive prostate cancer is permitted if at least 12 months have elapsed from last dose of docetaxel
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| NivolumabAlso: OPDIVO,, BMS-936558-01Specified dose on specified days | Biological | Arm A: Nivolumab + docetaxel + prednisone |
| PrednisoneSpecified dose on specified days | Drug | Arm A: Nivolumab + docetaxel + prednisone, Arm B: Placebo + docetaxel + prednisone |
| DocetaxelSpecified dose on specified days | Drug | Arm A: Nivolumab + docetaxel + prednisone, Arm B: Placebo + docetaxel + prednisone |
| PlaceboSpecified dose on specified days | Other | Arm B: Placebo + docetaxel + prednisone |
Primary outcome
Radiographic Progressive Free Survival (rPFS) Assessed by Blinded Independent Central Review (BICR) Per Prostate Cancer Working Group 3 (PCWG3)
Time frame: from randomization to the first date of documented progression or death due to any cause, whichever occurs first (up to approximately 31 months)
rPFS for randomized participants is the time between randomization and the first date of documented progression or death due to any cause, whichever occurs first. The rPFS was censored at the last radiographic tumor assessment up to the start of subsequent cancer therapy for those without progression or death. It was also censored at the date of last radiographic tumor assessment prior to the missed tumor assessments for participants who had progressive disease (PD) or death immediately after more than one consecutive missed tumor assessments. Radiographic progression is defined as at least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 millimeter (mm). The appearance of one or more new lesions is also considered progression.
Overall Survival (OS)
Time frame: From randomization to the date of death from any cause (Up to approximately 31 months)
OS for all randomized participants is the time between randomization and the date of death from any cause. For participants who are alive, their survival time was censored at the last date that they were known to be alive. OS was censored for participants at the date of randomization if they had no follow-up.
15 secondary outcomes
Objective Response Rate (ORR) Assessed by Blinded Independent Central Review (BICR) Per Prostate Cancer Working Group (PCWG3)
Time frame: From date of randomization to the date of objectively documented progression per PCWG3 or the date of subsequent systemic cancer therapy, whichever occurs first (Up to approximately 52 months)
Time to Response (TTR) Assessed by Blinded Independent Central Review (BICR) Per Prostate Cancer Working Group (PCWG3)
Time frame: From randomization to the date of the first documented CR or PR (Up to approximately 52 months)
Duration of Response Assessed by Blinded Independent Central Review (BICR) Per Prostate Cancer Working Group (PCWG3)
Time frame: From randomization date to the date of first documented radiographic progression or death due to any cause whichever occurs first (Up to approximately 52 months)
Prostate-specific Antigen (PSA) Response Rate (PSA-RR)
Time frame: Up to approximately 52 months
Time to PSA Progression (TTP-PSA)
Time frame: from randomization to the date of PSA Progression (Up to approximately 31 months)
Number of Participants With Adverse Events
Time frame: From first dose and 30 days after last dose of study therapy (Up to approximately 25 months)
Number of Participants With Serious Adverse Events
Time frame: From first dose and 30 days after last dose of study therapy (Up to approximately 25 months)
Number of Participants With Adverse Events Leading to Discontinuation
Time frame: From first dose and 30 days after last dose of study therapy (Up to approximately 25 months)
Number of Participants With Endocrine Immune-Mediated Adverse Events
Time frame: From first dose and 100 days after last dose of study therapy (Up to approximately 13 months)
Number of Participants With Non-Endocrine Immune-Mediated Adverse Events
Time frame: From first dose and 100 days after last dose of study therapy (Up to approximately 13 months)
Number of Participants With Select Adverse Events
Time frame: From first dose and 30 days after last dose of study therapy (Up to approximately 25 months)
Number of Participants Who Died
Time frame: Up to approximately 52 months
Number of Participants With Worst Common Terminology Criteria (CTC) Grade Laboratory Test Grade Change From Baseline
Time frame: From first dose and 30 days after last dose of study therapy (Up to approximately 25 months)
Number of Participants With Laboratory Abnormalities in Specific Thyroid Tests
Time frame: From first dose and 30 days after last dose of study therapy (Up to approximately 11 months)
Time to Pain Progression as Assessed by Brief Pain Inventory-Short Form (BPI-SF)
Time frame: From randomization to 1st pain symptoms at their worst over the last 24 hours (Up to approximately 31 months
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 12 Jun 2025.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Derived from this study: PubMed 41449150Fizazi K, Saad F, Alonso-Gordoa T, Zurawski B, Barthelemy P, Voog E, Javier Cutuli H, Buchler T, Ye D, Castellano D, Kwiatkowski M, Arslan C, Richardet M, Alifrangis C, Goh JC, Vianna K, Han W, Hatano K, Todenhofer T, Retz M, Srivastava A, Jin C, Gupta S, Trandafirescu G, Campos A, Lee CW, van Kooten Losio M, Subudhi SK. Nivolumab plus docetaxel versus placebo plus docetaxel for androgen receptor pathway inhibitor-pretreated and chemotherapy-naive metastatic castration-resistant prostate cancer (CheckMate 7DX): a double-blind, randomised, phase 3 trial. Lancet Oncol. 2026 Jan;27(1):68-78. doi: 10.1016/S1470-2045(25)00566-2.
- BMS Clinical Trial InformationLink provided by the sponsor.
- BMS Clinical Trial Patient RecruitingLink provided by the sponsor.
Related trials for Prostate Cancer
Active, not recruiting
Streamlined Geriatric and Oncological Evaluation Based On IC Technology
Breast Cancer, Comorbidities and Coexisting Conditions
Active, not recruitingObservational study
MRI Fusion Biopsy vs. Micro-Ultrasound Guided Biopsy
Prostate Cancer
Enrolling by invitationObservational study
Natural History Study of Early Life Exposures in Agriculture (ELEA)
Prostate Cancer, Leukemia
Not yet recruitingPhase 1/2
STAR0602 With Nivolumab in Non Small Cell Lung Cancer and in Metastatic Castrate-Resistant Prostate Cancer, and STAR0602 Alone in Thymic Carcinoma
NSCLC, Non-Small Cell Lung Cancer
Recruiting
Rehabilitation and Sex Therapy to Optimize Recovery After Prostate Cancer Treatment
Prostate Cancer, Urinary Incontinence
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Bristol-Myers Squibb study director
Bristol-Myers Squibb
293 sites in 28 countries: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 3 study testing Nivolumab, Prednisone and Docetaxel in people with Prostate Cancer, run by Bristol-Myers Squibb at 293 sites in 28 countries.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 8 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 12 Jun 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 293 sites in United States, China, Japan, France, Brazil and 23 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this phase mean?
Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
Yes. Results are posted in the registry (first posted 22 Jul 2024). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Radiographic Progressive Free Survival (rPFS) Assessed by Blinded Independent Central Review (BICR) Per Prostate Cancer Working Group 3 (PCWG3) (time frame: from randomization to the first date of documented progression or death due to any cause, whichever occurs first (up to approximately 31 months)). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT04100018, which also lists 1 linked publication.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 12 Jun 2025.